Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
LLY logo

Eli Lilly's Revenue Explodes 49% on Mounjaro and Zepbound Surge

LLY10-QFiling Date: 10/30/2025
Eli Lilly and Company
Description

What this story covers

Eli Lilly's Q3 2025 revenue soared 49% to $17B, driven by incretin therapies amid pipeline advances in obesity, Alzheimer's, and oncology. Strong cash flow supports R&D and acquisitions, though pricing pressures and regulations loom. No new risks reported.

Story snapshot

CompanyEli Lilly and Company
TickerLLY
VariantStandard detailed
Duration9:49
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000059478-25-000254

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in